Novartis Ag (NVS) Net Margin Growth (1y) (2010 - 2024)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Margin Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
1,568.00 |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-2,848.00 |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
-501.00 |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-5,859.00 |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-12.00 |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
931.00 |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
134.00 |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
3,053.00 |
| Dec 31, 2023 |
-5,859.00 |
| Jun 30, 2023 |
-2,014.00 |
| Mar 31, 2023 |
-18,707.00 |
| Dec 31, 2022 |
4,528.00 |
| Sep 30, 2022 |
-18,026.00 |
| Jun 30, 2022 |
-355.00 |
| Mar 31, 2022 |
4,860.00 |
| Dec 31, 2021 |
-201,434.00 |
| Sep 30, 2021 |
3,029.00 |
| Jun 30, 2021 |
-8.00 |
| Mar 31, 2021 |
10,175.00 |
| Mar 31, 2020 |
12,415.00 |
| Mar 31, 2019 |
-7,034.00 |
| Dec 31, 2018 |
-26,536.00 |
| Sep 30, 2018 |
-40,691.00 |
| Jun 30, 2018 |
-119,934.00 |
| Dec 31, 2017 |
23,797.00 |
| Sep 30, 2017 |
2,338.00 |
| Jun 30, 2017 |
84,728.00 |
| Dec 31, 2016 |
1,291.00 |
| Sep 30, 2016 |
-5,724,137.93 Bn |
| Mar 31, 2016 |
9.79 Bn |
| Dec 31, 2015 |
110,767.00 |
| Sep 30, 2015 |
5,724,137.93 Bn |
| Mar 31, 2015 |
-27,328.00 |
| Dec 31, 2010 |
354.95 Mn |
| Jun 30, 2010 |
399,454.00 |
